Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Total Current Liabilities (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Total Current Liabilities data on record, last reported at $21.9 million in Q3 2025.

  • For Q3 2025, Total Current Liabilities fell 9.39% year-over-year to $21.9 million; the TTM value through Sep 2025 reached $21.9 million, down 9.39%, while the annual FY2024 figure was $25.6 million, 43.73% down from the prior year.
  • Total Current Liabilities reached $21.9 million in Q3 2025 per PLX's latest filing, down from $24.1 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $96.2 million in Q2 2021 and bottomed at $21.9 million in Q3 2025.
  • Average Total Current Liabilities over 5 years is $40.1 million, with a median of $33.2 million recorded in 2021.
  • Peak YoY movement for Total Current Liabilities: crashed 67.83% in 2022, then soared 150.86% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $33.2 million in 2021, then fell by 2.25% to $32.4 million in 2022, then skyrocketed by 40.4% to $45.5 million in 2023, then plummeted by 43.73% to $25.6 million in 2024, then dropped by 14.35% to $21.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $21.9 million in Q3 2025, $24.1 million in Q2 2025, and $24.3 million in Q1 2025.